Endurant Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Endurant Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,982	Closed	-$1.82M	–	77
2022 Q1	$1.82M	Buy	+6,982	New	+$1.66M	0.48%	41
2021 Q3	–	Sell	-7,553	Closed	-$1.52M	–	65
2021 Q2	$1.52M	Buy	+7,553	New	+$1.58M	0.42%	51
2017 Q4	–	Sell	-21,900	Closed	-$3.33M	–	90
2017 Q3	$3.33M	Buy	+21,900	New	+$3.3M	1.01%	34
2016 Q4	–	Sell	-5,150	Closed	-$449K	–	89
2016 Q3	$449K	Sell	5,150 -1,100	-18%	-$104K	0.17%	77
2016 Q2	$538K	Sell	6,250 -2,500	-29%	-$216K	0.18%	73
2016 Q1	$696K	Sell	8,750 -9,500	-52%	-$859K	0.23%	63
2015 Q4	$2.3M	Sell	18,250 -8,450	-32%	-$1.02M	0.77%	42
2015 Q3	$2.78M	Sell	26,700 -6,200	-19%	-$797K	0.93%	39
2015 Q2	$4.06M	Buy	32,900 +18,500	+128%	+$2.33M	1.2%	30
2015 Q1	$1.7M	Buy	14,400 +3,600	+33%	+$431K	0.56%	57
2014 Q4	$1.28M	Buy	+10,800	New	+$1.22M	0.5%	55

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Endurant Capital Management's VRTX Position: Q2 2022 in Review

Endurant Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 6,982 shares — an estimated $1.82M sold.

Endurant Capital Management first reported a position in VRTX in Q4 2014 and held it in 11 quarters. The position peaked at $4.06M in Q2 2015. 1,109 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Endurant Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Endurant Capital Management sold 6,982 Vertex Pharmaceuticals shares in Q2 2022, an estimated $1.82M.
Endurant Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 11 quarters.
Endurant Capital Management's Vertex Pharmaceuticals position peaked at $4.06M in Q2 2015.
1,109 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.